These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9109538)

  • 21. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
    Banati RB; Daniel SE; Blunt SB
    Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
    Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
    Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of electroacupuncture intervention on levels of SOD, GSH, GSH-Px, MDA, and apoptosis of dopaminergic neurons in substantia Nigra in rats with Parkinson's disease].
    Li J; Wang LN; Xiao HL; Li X; Yang JJ
    Zhen Ci Yan Jiu; 2014 Jun; 39(3):185-91. PubMed ID: 25069193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability.
    Pieper HC; Evert BO; Kaut O; Riederer PF; Waha A; Wüllner U
    Neurobiol Dis; 2008 Dec; 32(3):521-7. PubMed ID: 18930140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
    Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
    Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ageing and Parkinson's disease: substantia nigra regional selectivity.
    Fearnley JM; Lees AJ
    Brain; 1991 Oct; 114 ( Pt 5)():2283-301. PubMed ID: 1933245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human GABA A receptors on dopaminergic neurons in the pars compacta of the substantia nigra.
    Petri S; Krampfl K; Dengler R; Bufler J; Weindl A; Arzberger T
    J Comp Neurol; 2002 Oct; 452(4):360-6. PubMed ID: 12355418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of mitochondria in Parkinson disease.
    Kösel S; Hofhaus G; Maassen A; Vieregge P; Graeber MB
    Biol Chem; 1999; 380(7-8):865-70. PubMed ID: 10494835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
    Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
    Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons.
    Tompkins MM; Basgall EJ; Zamrini E; Hill WD
    Am J Pathol; 1997 Jan; 150(1):119-31. PubMed ID: 9006329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovering genes with localised expression in the mouse brain: cDNAs specific to the substantia nigra.
    Savioz A; Davies RW
    Gene; 1995 Mar; 154(2):225-30. PubMed ID: 7890168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson's disease autopsies.
    Moos T; Jensen PH
    Acta Neuropathol; 2004 Jan; 107(1):23-6. PubMed ID: 13680279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Schapira AH; Mann VM; Cooper JM; Krige D; Jenner PJ; Marsden CD
    Ann Neurol; 1992; 32 Suppl():S116-24. PubMed ID: 1510369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuronal death caused by apoptosis in Parkinson disease].
    Ruberg M; France-Lanord V; Brugg B; Lambeng N; Michel PP; Anglade P; Hunot S; Damier P; Faucheux B; Hirsch E; Agid Y
    Rev Neurol (Paris); 1997 Sep; 153(8-9):499-508. PubMed ID: 9683999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.
    Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR
    Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of microRNA-183 promotes apoptosis of substantia nigra neurons via the inhibition of OSMR in a mouse model of Parkinson's disease.
    Gao JX; Li Y; Wang SN; Chen XC; Lin LL; Zhang H
    Int J Mol Med; 2019 Jan; 43(1):209-220. PubMed ID: 30431059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease.
    Hartley A; Stone JM; Heron C; Cooper JM; Schapira AH
    J Neurochem; 1994 Nov; 63(5):1987-90. PubMed ID: 7931358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury.
    Kholodilov NG; Neystat M; Oo TF; Lo SE; Larsen KE; Sulzer D; Burke RE
    J Neurochem; 1999 Dec; 73(6):2586-99. PubMed ID: 10582622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.